Market Analysis and Insights: Global Hereditary Cancer Testing Market
Hereditary cancer testing is a process of identifying an inherited gene mutation that increases the risk of cancer development. It mainly includes predictive genetic testing and clinical DNA sequencing, in predictive genetic testing, patient’s family history is analyzed for any inherited mutation from ancestry. In DNA sequencing, entire DNA or genome of an individual is analyzed. It is useful for testing many genetic mutations at a time.
The global Hereditary Cancer Testing market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, RNA Testing accounting for % of the Hereditary Cancer Testing global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Breast Cancer segment is altered to an % CAGR throughout this forecast period.
China Hereditary Cancer Testing market size is valued at US$ million in 2021, while the North America and Europe Hereditary Cancer Testing are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Hereditary Cancer Testing landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hereditary Cancer Testing market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hereditary Cancer Testing market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hereditary Cancer Testing market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hereditary Cancer Testing market.
Global Hereditary Cancer Testing Scope and Market Size
Hereditary Cancer Testing market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Hereditary Cancer Testing market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
RNA Testing
DNA Testing
Segment by Application
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Other Cancers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Ambry Genetics (Konica Minota)
Asper Biogene
Natera
Caris Life Sciences
BioReference Laboratories (GeneDx)
LabSolutions
Progenity，Inc
ARUP Laboratories
Myriad
NeoGenomics
Blueprint Genetics
CellMax Life
Fulgent Genetics
Strand Life Sciences
Myogenes
LabCorp
Quest Diagnostics
Pathway Genomics